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e136 Lettersbe aware that radiosensitization may be associated
with vemurafenib administration and carefully
monitor patients receiving concomitant radiotherapy,
as well as patients who start vemurafenib after
radiotherapy. Neither radiotherapy nor vemurafenib
need be stopped if radiation dermatitis develops, in
that reported cases resolved without further adverse
events after topical corticosteroid administration,
cessation of radiotherapy, or both.
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Treatment of epidermolysis bullosa
pruriginosa using systemic and topical agents
To the Editor: A 46-year-old Hispanic woman pre-
sented to our dermatology clinic with a 6-year history
of an intermittent pruritic vesicobullous eruption on
her lower legs and, to a lesser extent, on her forearms
(Fig 1, A). She had failed to respond to prior
treatments, including topical and intralesional corti-
costeroids, mycophenolate mofetil, and photother-
apy. There was no family history of a similar
condition. Histologic findings showed subepidermal
clefts with minimal inflammation. Direct immuno-
fluorescence on perilesional skin was negative. A
complete workup for immunobullous disease and
porphyria was negative. Electron microscopy
demonstrated separation of the sublamina densa
with a reduced number of anchoring fibrils, which
Open access under CC BY-NC-ND license.was clinically consistent with dystrophic epidermol-
ysis bullosa pruriginosa (EBP). DNA extraction from
peripheral blood followed by bidirectional COL7A1
gene sequencing (GeneDx, Gaithersburg, MD) re-
vealed a novel compound heterozygotic mutation; a
guanine (G) to cytosine (C) splice site mutation at the
beginning of intron 51 (IVS5111 G/C) and adenine
(A) to thymine (T) resulting in a codon mutation of
glutamine (Gln) to leucine (Leu) at position 1924
( p.Gln1924Leu) on exon 69.
Pruritus and excoriation are critical in unmasking
skin fragility in EBP. Given the pauci-inflammatory
nature of EBP, we focused on the control of pruritus
with the use of ketamine 0.5% and amitriptyline 2%
(KA) topical gel. With regular use of KA gel, the
patient described a 90% decrease in localized pruri-
tus and blistering. Subsequently, the patient was
started on sertraline for depressive symptoms. Over
the 6-month period on oral sertraline and KA gel,
the patient had virtually complete resolution of
localized and generalized pruritus with minor
relapses (Fig 1, B).
Effective treatment of EBP is challenging, and
long-term outcomes are rarely described in the
literature. Treatments reported to date include corti-
costeroids, antihistamines, cryotherapy, tacrolimus,
cyclosporine, and thalidomide.1 However, control of
inflammation has not demonstrated consistent effi-
cacy. Based on the structural fragility of EBP,
unmasked by severe pruritus and scratching, we
advocate focusing the treatment on the control of
pruritus, minimizing trauma, and managing lower
extremity edema. Topical KA is thought to act pre-
and post-axonally in the transmission of pain and
possibly pruritus. Poterucha et al2 showed that
topical KA had a 62% response rate in a wide variety
of cutaneous disorders, without inducing systemic
side effects.2,3 Interestingly, the concomitant use of
sertraline for mild depressive symptoms further
improved the patient’s generalized pruritus and
EBP. Sertraline has been reported as a first-line
treatment for cholestatic pruritus and implicates
serotonergic mediators in the pruritus of EBP.4 The
exact mechanism of action is unknown but is
thought to have a regulatory action on the trans-
mission of itch signals.5
The efficacy and minimal medication risk with
the combined oral and topical therapies reported
here favor this approach as a primary treatment of
EBP, a disease that necessitates long-term manage-
ment. Additional studies are required to further
validate the efficacy of systemic sertraline and
topical KA for treatment of EBP and possibly other
skin conditions in which pruritus plays a key
pathogenic role.
Fig 1. Epidermolysis bullosa pruriginosa. A, Purple polygonal flat-topped papules coalescing
into large, linear plaques. Bullae occurred on the top of several of these plaques. B, Area shown
in A 6 months after treatment with residual postinflammatory hyperpigmentation and scarring.
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http://dx.doi.org/10.1016/j.jaad.2013.12.011Orofacial granulomatosis successfully treated
with mycophenolate mofetil
To the Editor: Orofacial granulomatosis (OFG) is a
chronic, relapsing, potentially disfiguring inflamma-
tory disorder of unknown etiology.1 It is character-
ized by persistent enlargement of the orofacial
tissues and noncaseating granulomatous inflamma-
tion on tissue biopsy in the absence of diagnosable
Crohn disease or sarcoidosis.1-3 It is thought that
OFG represents a spectrum of disease ranging from
localized granulomatous inflammation of the lips
(cheilitis granulomatosa, Miescher cheilitis) to
persistent lip or facial swelling with mucosal ulcer-
ation, recurrent facial paralysis, and lingual fissuring
(Melkersson-Rosenthal syndrome).2,3 Due to its
unknown etiology and unpredictable clinical
course, no definitive pharmacologic therapy is yet
available.1,2 We present a case of OFG successfully
treated with mycophenolate mofetil (MMF), sug-
gesting this treatment may be of benefit in these
patients.
A 59-year-old Caucasian woman with a history of
systemic lupus erythematosus, hepatitis C, and
recurrent herpes labialis presented with a 4-month
history of rash and swelling of her upper lip. The
lesion started as a ‘‘cold sore’’ with occasional
burning and mild pruritus. She was treated with
oral steroids and amoxicillin by her primary care
physician with temporary relief and was referred for
further evaluation by a dermatologist. Her condition
was persistent with erythema, mild scaling, and
diffuse swelling of the upper lip extending to the
right oral commissure and lower lip. No other oral
mucosal or lingual lesions were noted and she
